Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Lab studies show two proteins prevented progressive nerve cell loss in Parkinson’s disease

09.09.2004


In recent years, scientists have made important strides in developing drugs that help patients manage the symptoms of Parkinson’s Disease – a chronic, progressive movement disorder affecting as many as one million Americans. But despite their effectiveness, the drugs don’t stop Parkinson’s disease from progressing, causing patients’ symptoms to eventually grow worse in spite of medication.



Now, researchers at Cedars-Sinai Medical Center have found that two specific proteins – "Sonic Hedgehog" and "Gli-1" – delivered via a genetically engineered virus into the brains of laboratory rats, prevented the progressive degeneration of nerve cells in the brain that cause Parkinson’s disease. The study, published in the September issue of the journal, Molecular Therapy, may lead to a new way to treat patients with advanced Parkinson’s Disease.

"Our results establish, for the first time, that viral transfer of Sonic hedgehog and Gli-1 - two proteins that are involved in early brain development, but are no longer present in the adult brain – may provide a new strategy to prevent progressive degeneration of the nerve cells in the brain that cause Parkinson’s disease," said Pedro Lowenstein, M.D., Ph.D., Director of the Gene Therapeutics Research Institute at Cedars-Sinai Medical Center, and a Professor of Medicine and Pharmacology at UCLA.


Parkinson’s disease occurs when the nerve cells in the part of the brain known as the "substantia nigra" that produce a chemical called dopamine begin to malfunction and progressively die. Dopamine acts as a chemical messenger to send signals to a part of the brain called the basal ganglia that controls movement and coordination. But as more of these cells die, less and less dopamine is produced, causing Parkinson’s disease.

To treat the symptoms of Parkinson’s disease, doctors rely on various types of drugs that work by helping to replenish dopamine. A drug called L-DOPA (levodopa), for example, is absorbed in the brain and changed into dopamine. Other drugs, work differently by either prolonging the effect of levodopa-formed dopamine or by actually mimicking dopamine. But regardless of how they work, patients often have to take more than one drug to either enhance the drug’s effects or to reduce the side effects that many of the drugs cause. As more cells die during the progression of the disease, these drugs lose their effectiveness.

"Because these drugs don’t stop the disease from progressing, we used a genetically engineered viral vector to deliver very specific molecules to see whether they would prevent the nerve cells in the brain from dying in adult rats with Parkinson’s," commented Maria Castro, Ph.D., Co-Director of the Gene Therapeutic Research Institute at Cedars-Sinai and a senior author of the study. "Ultimately, because we found that two of these molecules prevented cell death, we aim to translate this type of gene therapy into a clinical trial to determine whether it will stop the progression of the disease. Importantly, Sonic Hedgehog and Gli1, display novel mechanisms of action compared to other drugs utilized so far."

Genetically engineered viruses are used to transport genes and/or proteins into cells and have been used in gene therapy research for the last ten years. Just like a viral infection, they work by tricking cells into accepting them as part of their own genetic coding. The trick has been to alter the virus so that it delivers the desired genetic material, while removing any characteristics that make the virus dangerous.

To make viruses safe and effective, scientists remove the genetic coding that causes infection and engineer them so that they stop reproducing. The adenoviral vector used in this study, for example, has been genetically manipulated to selectively express proteins that can protect the neurons that are damaged during the course of Parkinson’s disease.

"Currently, we are constructing other versions of this virus that could eventually be used in clinical trials in humans that are safe even when the body mounts an immune response, and that could be switched ’on’ and ’off’ at will," said Dr. Castro. "In other words, these new viral vectors would effectively resist any attack by the immune system and have built-in switches that allow the doctor to regulate the delivery of the neuroprotective proteins as needed."

In the laboratory study, the investigators used an adenoviral vector to test the effectiveness of three proteins: Sonic Hedgehog (Shh), a signaling molecule that plays a key role in the development of the brain but is no longer present in the adult brain; Gli-1, a protein that turns genes on and off within the same signaling pathway; and Nurr1, a protein receptor that is needed to produce substantia nigra neurons in the brain.

To determine whether any of the three proteins would prevent nerve cells in the brain from dying, the investigators injected Shh, Gli-1 and Nurr1 into the brains of laboratory rats with Parkinson’s disease. The investigators found that nerve cells in the rats treated with Shh and Gli1, were protected, while no effect was seen in those treated with Nurr1.

"Given that these proteins are only present in the developing brain, our study demonstrates that we were able to use a genetically engineered virus to deliver them into the adult brains of laboratory rats with Parkinson’s disease and that they significantly protected nerve cells from dying," said Dr. Lowenstein.

Kelli Hanley | EurekAlert!
Further information:
http://www.cshs.org

More articles from Studies and Analyses:

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

nachricht Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>